Today: 7 February 2026
Subscribe
Browse Category

Health News News 6 January 2026 - 2 February 2026

Johnson & Johnson stock rises as new Erleada survival data lands

Johnson & Johnson stock rises as new Erleada survival data lands

Johnson & Johnson shares rose 0.8% to $229.09 midday after the company reported real-world data showing Erleada cut the risk of death by 51% over 24 months versus darolutamide in advanced prostate cancer. The move tracked broader U.S. market gains. Investors await further feedback from doctors and insurers, and key dates including a Feb. 24 ex-dividend.
2 February 2026
····
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
······
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
····
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Ottawa, January 9, 2026, 14:59 EST Costco Wholesale Canada told customers who bought certain Peace by Chocolate gift boxes online to stop eating two pistachio-containing chocolates, after an ingredient supplier triggered a warning over possible Salmonella contamination. The “voluntary, precautionary” recall covers Our Classic Box – 15 assorted filled chocolates (lot codes — the batch numbers on the packaging — 25284/2026OC11, 25297/2026OC24, 25247/2026SE04, 25251/2026SE08, 25329/2026NO25) and The Harmony Bar (25245/2027FE28, 25322/2027MA18, 25300/2027AL22, 25280/2027AL06, 25281/2027AL06) included in Peace by Chocolate Small and Medium Bestsellers Boxes purchased on Costco.ca between Sept. 7 and Dec. 3, the notice showed. (Costco Customer Service) The
9 January 2026
·
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

New York, Jan 7, 2026, 18:52 EST — After-hours Merck & Co (MRK.N) shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus (HPV) vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov The CDC move lands at an awkward moment for Merck, which relies on Gardasil as its biggest vaccine franchise and a key growth lever alongside cancer drug Keytruda. Jefferies
8 January 2026
·····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

New York, Jan 6, 2026, 10:40 EST — Regular session Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14. The move extends a rebound sparked by the U.S. rollout of a pill version of Wegovy, a franchise that has become central to how investors value the Danish drugmaker’s growth story. The launch matters now because the obesity market is shifting from a supply-driven boom to a fight over price, convenience and who pays. Novo needs the pill to widen demand without triggering a margin-eroding price
6 January 2026
····
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

New York, January 6, 2026, 07:27 EST — Premarket Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public The launch lands as investors debate how fast the obesity-drug boom can grow without forcing deeper price cuts. It also puts fresh focus on political pressure in Washington to bring down prices for widely used weight-loss medicines. Novo’s push into pills matters because it aims at patients who
6 January 2026
····
Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight

Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight

New York, January 5, 2026, 21:32 (EST) — Market closed Merck & Co shares dipped in late trading on Monday after U.S. health officials rewrote the childhood and adolescent immunization schedule, including a change to a one-dose recommendation for the human papillomavirus (HPV) vaccine. Merck (MRK.N) closed up 0.93% at $107.44 and was last down 0.22% at $107.20 after the bell. Yahoo Finance The shift matters for Merck because Gardasil 9 is the only HPV vaccine available for use in the United States, and the CDC’s guidance helps shape how physicians counsel families. Even modest changes in dosing guidance can
6 January 2026
···
1 2 3 4

Stock Market Today

Go toTop